Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The liver and pancreas are the main actors in glucose metabolism, but not the only ones. Muscles, adipose tissue and the brain play different roles. However, the prize for the best new actor in ...

Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.

"Overall, metabolic responses to glucagon stimulation in individuals with type 1 diabetes are comparable to those in healthy ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

The following is a summary of “Metabolic Effects of Glucagon Stimulations in Type 1 Diabetes and Healthy Controls,” published ...

The two organizations will produce educational materials about the medicine and its importance for people living with type 1 ...

Ascletis Pharma has reported positive topline outcomes from its US Phase Ia SAD study of the oral tablet, ASC30, in obese ...

Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...

These results have also already contributed to the WHO recommendations on the use of a two-dose schedule", concludes Andrew Azman.

The latest buzz around the popular weight loss drugs Ozempic, Mounjaro and Wegovy is to reduce the doseage to avoid the negative effects of normal doses. But does it have dangers too? Jessica Salter r ...